Skip to Main Content

Author Details

Yu Chen
School of Pharmacy, University of Wisconsin-Madison
2008
73
37
PMIDPaper TitleJournal TitlePublished Year
37094179Small-Molecule Ferritin Degrader as a Pyroptosis Inducer.J Am Chem Soc2023
37502956NSD2 maintains lineage plasticity and castration-resistance in neuroendocrine prostate cancer.bioRxiv2023
37018402ETV4 mediates dosage-dependent prostate tumor initiation and cooperates with p53 loss to generate prostate cancer.Sci Adv2023
36989364Active recruitment of anti-PD-1-conjugated platelets through tumor-selective thrombosis for enhanced anticancer immunotherapy.Sci Adv2023
37295433Minor intron splicing is critical for survival of lethal prostate cancer.Mol Cell2023
37196699Cell-based relay delivery strategy in biomedical applications.Adv Drug Deliv Rev2023
34802033Prognostic and therapeutic significance of COP9 signalosome subunit CSN5 in prostate cancer.Oncogene2022
35617398Chromatin profiles classify castration-resistant prostate cancers suggesting therapeutic targets.Science2022
35612089Recent advances in biomaterial-assisted cell therapy.J Mater Chem B2022
35789380PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.Cancer Discov2022
35759660Delta-like ligand 3-targeted radioimmunotherapy for neuroendocrine prostate cancer.Proc Natl Acad Sci U S A2022
35713468Proteolysis-targeting chimera (PROTAC) delivery system: advancing protein degraders towards clinical translation.Chem Soc Rev2022
36564410Author Correction: FOXA1 repression drives lineage plasticity and immune heterogeneity in bladder cancers with squamous differentiation.Nat Commun2022
36367930Mucoadhesive probiotic backpacks with ROS nanoscavengers enhance the bacteriotherapy for inflammatory bowel diseases.Sci Adv2022
36323682FOXA1 repression drives lineage plasticity and immune heterogeneity in bladder cancers with squamous differentiation.Nat Commun2022
35981096Lineage plasticity in prostate cancer depends on JAK/STAT inflammatory signaling.Science2022
35041493Phase II Trial of Imatinib Plus Binimetinib in Patients With Treatment-Naive Advanced Gastrointestinal Stromal Tumor.J Clin Oncol2022
35110417Phase Ib Trial of the Combination of Imatinib and Binimetinib in Patients with Advanced Gastrointestinal Stromal Tumors.Clin Cancer Res2022
34667026Differences in Prostate Cancer Genomes by Self-reported Race: Contributions of Genetic Ancestry, Modifiable Cancer Risk Factors, and Clinical Factors.Clin Cancer Res2022
32859606Pleiotropic Mechanisms Drive Endocrine Resistance in the Three-Dimensional Bone Microenvironment.Cancer Res2021
33558541Distinct mechanisms for TMPRSS2 expression explain organ-specific inhibition of SARS-CoV-2 infection by enzalutamide.Nat Commun2021
34417459Defining the therapeutic selective dependencies for distinct subtypes of PI3K pathway-altered prostate cancers.Nat Commun2021
33288675Direct evidence that the GPCR CysLTR2 mutant causative of uveal melanoma is constitutively active with highly biased signaling.J Biol Chem2021
33229459Combined Inhibition of Gα<sub>q</sub> and MEK Enhances Therapeutic Efficacy in Uveal Melanoma.Clin Cancer Res2021
32220959Modulation of androgen receptor DNA binding activity through direct interaction with the ETS transcription factor ERG.Proc Natl Acad Sci U S A2020
33144576Role of specialized composition of SWI/SNF complexes in prostate cancer lineage plasticity.Nat Commun2020
33053353GNA11 Q209L Mouse Model Reveals RasGRP3 as an Essential Signaling Node in Uveal Melanoma.Cell Rep2020
32807988Single-cell transcriptomics identifies a distinct luminal progenitor cell type in distal prostate invagination tips.Nat Genet2020
31085180CHD1 Loss Alters AR Binding at Lineage-Specific Enhancers and Modulates Distinct Transcriptional Programs to Drive Prostate Tumorigenesis.Cancer Cell2019
31559706The novel BET-CBP/p300 dual inhibitor NEO2734 is active in SPOP mutant and wild-type prostate cancer.EMBO Mol Med2019
31439587PARP Inhibition Suppresses GR-MYCN-CDK5-RB1-E2F1 Signaling and Neuroendocrine Differentiation in Castration-Resistant Prostate Cancer.Clin Cancer Res2019
31296553Aberrant Expression of ERG Promotes Resistance to Combined PI3K and AR Pathway Inhibition through Maintenance of AR Target Genes.Mol Cancer Ther2019
31597964Spliceosomal disruption of the non-canonical BAF complex in cancer.Nature2019
29162563FOXF1 Defines the Core-Regulatory Circuitry in Gastrointestinal Stromal Tumor.Cancer Discov2018
29880008Basket trial of TRK inhibitors demonstrates efficacy in TRK fusion-positive cancers.J Hematol Oncol2018
29921838Patient derived organoids to model rare prostate cancer phenotypes.Nat Commun2018
29508246A phase II study of the dual mTOR inhibitor MLN0128 in patients with metastatic castration resistant prostate cancer.Invest New Drugs2018
29202479SPOP mutation drives prostate neoplasia without stabilizing oncogenic transcription factor ERG.J Clin Invest2018
27935821Stromal hedgehog signaling maintains smooth muscle and hampers micro-invasive prostate cancer.Dis Model Mech2017
28292441SPOP Mutation Drives Prostate Tumorigenesis In Vivo through Coordinate Regulation of PI3K/mTOR and AR Signaling.Cancer Cell2017
29153843Aberrant Activation of a Gastrointestinal Transcriptional Circuit in Prostate Cancer Mediates Castration Resistance.Cancer Cell2017
28678785Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway.Nature2017
28539323ETV1-Positive Cells Give Rise to <i>BRAF<sup>V600E</sup></i> -Mutant Gastrointestinal Stromal Tumors.Cancer Res2017
28534535The potential of organoids in urological cancer research.Nat Rev Urol2017
26977337Miniature in vivo MEMS-based line-scanned dual-axis confocal microscope for point-of-care pathology.Biomed Opt Express2016
27728805N-Myc Induces an EZH2-Mediated Transcriptional Program Driving Neuroendocrine Prostate Cancer.Cancer Cell2016
27536883A Tmprss2-CreERT2 Knock-In Mouse Model for Cancer Genetic Studies on Prostate and Colon.PLoS One2016
27264179A Computational Drug Repositioning Approach for Targeting Oncogenic Transcription Factors.Cell Rep2016
27089179Recurrent activating mutations of G-protein-coupled receptor CYSLTR2 in uveal melanoma.Nat Genet2016
26797458Organoid culture systems for prostate epithelial and cancer tissue.Nat Protoc2016
  • 1 - 50 of 73

Recommended Authors

George V Thomas
Knight Cancer Institute, Oregon Health and Science University
Career Start Year 2016
Number of shared co-authors 7
Wei Yuan
The Institute for Cancer Research
Career Start Year 2015
Number of shared co-authors 33
Joshua Armenia
Oncology R&D
Career Start Year 2013
Number of shared co-authors 48
Xinpei Ci
Princess Margaret Cancer Centre, University Health Network
Career Start Year 2013
Number of shared co-authors 12
Anjali V Sheahan
Dana-Farber Cancer Institute
Career Start Year 2012
Number of shared co-authors 15
Adam G Sowalsky
National Cancer Institute
Career Start Year 2010
Number of shared co-authors 21
Anne Haegert
University of British Columbia
Career Start Year 2008
Number of shared co-authors 15
Brian W Simons
Center for Comparative Medicine, Baylor College of Medicine
Career Start Year 2008
Number of shared co-authors 8
Alastair Davies
University of British Columbia
Career Start Year 2008
Number of shared co-authors 8
Leigh Ellis
Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center
Career Start Year 2007
Number of shared co-authors 31
Jonathan Chou
University of California san francisco
Career Start Year 2005
Number of shared co-authors 21
Michael C Haffner
Fred Hutchinson Cancer Center
Career Start Year 2005
Number of shared co-authors 38
Mitchell G Lawrence
Biomedicine Discovery Institute, Monash University
Career Start Year 2005
Number of shared co-authors 5
Alok K Tewari
Dana-Farber Cancer Institute, Harvard Medical School
Career Start Year 2005
Number of shared co-authors 7
Robert H Bell
University of British Columbia
Career Start Year 2004
Number of shared co-authors 13
Adam Sharp
The Institute for Cancer Research
Career Start Year 2003
Number of shared co-authors 33
Xiaohu Zhang
National Center for Advancing Translational Sciences
Career Start Year 2003
Number of shared co-authors 0
Ladan Fazli
University of British Columbia
Career Start Year 2002
Number of shared co-authors 35
Sooryanarayana Varambally
University of Alabama at Birmingham, USA O'Neal Comprehensive Cancer Center
Career Start Year 2001
Number of shared co-authors 32
Ilsa Coleman
Fred Hutchinson Cancer Center
Career Start Year 2001
Number of shared co-authors 55
Jiaoti Huang
Duke University School of Medicine
Career Start Year 2000
Number of shared co-authors 27
Amina Zoubeidi
University of British Columbia
Career Start Year 2000
Number of shared co-authors 36
Renea A Taylor
Peter MacCallum Cancer Centre
Career Start Year 1999
Number of shared co-authors 8
Srinivasan Yegnasubramanian
Johns Hopkins University School of Medicine
Career Start Year 1999
Number of shared co-authors 24
Joshi J Alumkal
Rogel Cancer Center, University of Michigan ann arbor
Career Start Year 1999
Number of shared co-authors 42
Kristiina Iljin
VTT Technical Research Centre of Finland Ltd
Career Start Year 1999
Number of shared co-authors 1
Ian G Mills
Queen's University Belfast
Career Start Year 1997
Number of shared co-authors 14
Matthew B Rettig
David Geffen School of Medicine, University of California los angeles
Career Start Year 1995
Number of shared co-authors 36
Ganesh V Raj
University of Texas Southwestern Medical Center at Dallas
Career Start Year 1994
Number of shared co-authors 27
Christopher M Hovens
Royal Melbourne Hospital, The University of Melbourne
Career Start Year 1989
Number of shared co-authors 5

Collaborators

Charles L Sawyers
Memorial Sloan Kettering Cancer Center
Co-authored papers 23
Howard I Scher
Memorial Sloan Kettering Cancer Center
Co-authored papers 16
Andrea Sboner
Institute for Computational Biomedicine
Co-authored papers 14
Mark A Rubin
University of Bern
Co-authored papers 13
Anuradha Gopalan
Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center
Co-authored papers 13
Himisha Beltran
Dana-Farber Cancer Institute
Co-authored papers 10
Cristina R Antonescu
Memorial Sloan Kettering Cancer Center
Co-authored papers 8
Deyou Zheng
Co-authored papers 8
Juan Miguel Mosquera
Caryl and Israel Englander Institute for Precision Medicine
Co-authored papers 8
Brian D Robinson
Sandra and Edward Meyer Cancer Center
Co-authored papers 7
Michael F Berger
Co-authored papers 6
Olivier Elemento
Meyer Cancer Center
Co-authored papers 6
Michael J Morris
Memorial Sloan Kettering Cancer Center
Co-authored papers 6
Francesca Demichelis
University of Trento
Co-authored papers 5
Victor E Reuter
Memorial Sloan Kettering Cancer Center
Co-authored papers 5
Nikolaus Schultz
Memorial Sloan Kettering Cancer Center
Co-authored papers 5
Dana E Rathkopf
Memorial Sloan Kettering Cancer Center
Co-authored papers 5
Loredana Puca
Sandra and Edward Meyer Cancer Center
Co-authored papers 4
Philip W Kantoff
Memorial Sloan Kettering Cancer Center
Co-authored papers 4
Elisa de Stanchina
Co-authored papers 4
Richard Koche
Memorial Sloan Kettering Cancer Center
Co-authored papers 4
Wassim Abida
Memorial Sloan Kettering Cancer Center
Co-authored papers 4
Joanna Cyrta
Paris Sciences Lettres University PSL, Institut CURIE
Co-authored papers 4
Hans Clevers
Princess Maxima Center for Pediatric Oncology
Co-authored papers 3
Scott T Tagawa
Meyer Cancer Center, Weill Cornell Medicine-NewYork Presbyterian Hospital
Co-authored papers 3
Stephen B Solomon
Memorial Sloan-Kettering Cancer Center
Co-authored papers 3
David M Nanus
Sandra and Edward Meyer Cancer Center
Co-authored papers 3
Rohan Bareja
Case Western Reserve University
Co-authored papers 3
Kenneth Eng
Caryl and Israel Englander Institute for Precision Medicine
Co-authored papers 3
Mirjam Blattner
Co-authored papers 3
Release 1.2